Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Candoni A, Papayannidis C, Martinelli G, Simeone E, Gottardi M, Iacobucci I, Gherlinzoni F, Visani G, Baccarani M, Fanin R. Candoni A, et al. Among authors: gherlinzoni f. Am J Hematol. 2018 May;93(5):655-663. doi: 10.1002/ajh.25057. Epub 2018 Mar 2. Am J Hematol. 2018. PMID: 29396857 Free article. Clinical Trial.
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
Mosna F, Papayannidis C, Martinelli G, Di Bona E, Bonalumi A, Tecchio C, Candoni A, Capelli D, Piccin A, Forghieri F, Bigazzi C, Visani G, Zambello R, Zanatta L, Volpato F, Paolini S, Testoni N, Gherlinzoni F, Gottardi M. Mosna F, et al. Among authors: gherlinzoni f. Am J Hematol. 2015 Jun;90(6):515-23. doi: 10.1002/ajh.24000. Epub 2015 Apr 1. Am J Hematol. 2015. PMID: 25753065 Free article.
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S, Ottaviani E, Ferrari A, Michelutti A, Simeone E, Astolfi A, Abbenante MC, Parisi S, Cattina F, Malagola M, Russo D, Damiani D, Gherlinzoni F, Gottardi M, Baccarani M, Fanin R, Martinelli G. Iacobucci I, et al. Among authors: gherlinzoni f. Pharmacogenomics J. 2013 Aug;13(4):335-41. doi: 10.1038/tpj.2012.13. Epub 2012 May 15. Pharmacogenomics J. 2013. PMID: 22584460
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Among authors: gherlinzoni f. Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30. Am J Hematol. 2017. PMID: 28466557 Free article.
Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia.
Gottardi M, Mosna F, de Angeli S, Papayannidis C, Candoni A, Clavio M, Tecchio C, Piccin A, dell'Orto MC, Benedetti F, Martinelli G, Gherlinzoni F. Gottardi M, et al. Among authors: gherlinzoni f. Hematol Rep. 2017 Sep 26;9(3):7029. doi: 10.4081/hr.2017.7028. eCollection 2017 Sep 26. Hematol Rep. 2017. PMID: 29071049 Free PMC article. No abstract available.
Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C, Candoni A, Zannier ME, Olivieri J, Imbergamo S, Caizzi M, Nadali G, Di Bona E, Ermacora A, Gottardi M, Facchinelli D, Ciancia R, Lazzarotto D, Dubbini MV, Festini G, Gherlinzoni F, Michieli MG, Semenzato G, Fanin R. Filì C, et al. Among authors: gherlinzoni f. Leuk Res. 2019 Jan;76:33-38. doi: 10.1016/j.leukres.2018.11.015. Epub 2018 Nov 28. Leuk Res. 2019. PMID: 30529681
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Blood. 2009 Apr 9;113(15):3428-34. doi: 10.1182/blood-2007-08-103499. Epub 2009 Feb 11. Blood. 2009. PMID: 19211938 Free article. Clinical Trial.
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.
Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party. Gugliotta G, et al. Among authors: gherlinzoni f. Blood. 2011 May 26;117(21):5591-9. doi: 10.1182/blood-2010-12-324228. Epub 2011 Mar 30. Blood. 2011. PMID: 21450900 Free article.
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G, Lemoli R, Tosi P, Martinelli G, Testoni N, Ricci P, Motta M, Gherlinzoni F, Leopardi G, Pastano R, Rizzi S, Piccaluga P, Isidori A, Tura S. Visani G, et al. Among authors: gherlinzoni f. Bone Marrow Transplant. 1999 Sep;24(5):467-72. doi: 10.1038/sj.bmt.1701920. Bone Marrow Transplant. 1999. PMID: 10482929
249 results